A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

201683 citationsJournal Article

Authors

Good health and well-being

Published in: Investigational New Drugs

Volume 34, Issue 5, pp. 604-613

Field-Weighted Citation Impact: 4.58